Esketamine : New drug for depression approved by the FDA

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class.

This article published in the New England Journal of Medicine
N Engl J Med 2019; 381:1-4 DOI: 10.1056/NEJMp1903305

discusses Esketamine approval for treatment-resistant depression.

The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s